Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Rare Case of Extramammary Paget Disease With Concurrent Herpes Simplex Virus Infection: Three-Color Immunohistochemical Analysis for Re-Evaluating Previous Hypotheses.

Pathology international·2026
Same author

GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.

Pituitary·2026
Same author

A Homology-Based Application to Diagnose Colorectal Adenoma and Early-Stage Cancer.

Pathology international·2026
Same author

Adrenal Primary Ganglioneuroblastoma Presenting in Adulthood: A Case Report.

IJU case reports·2026
Same author

Pulmonary <i>Mycobacterium shigaense</i> Infection with Hemoptysis: Two Surgically Resected Case Reports.

Surgical case reports·2026
Same author

Fibroblast activation protein inhibitor-PET/CT in lung cancer: a prospective single-center study with histopathological correlation of fibroblast activation protein expression.

International journal of clinical oncology·2026

Related Experiment Video

Updated: Mar 1, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Effect of plasma-activated medium on the decrease of tumorigenic population in lymphoma.

Naoki Wada1, Jun-Ichiro Ikeda1, Hiromasa Tanaka2

  • 1Department of Pathology, Osaka University Graduate School of Medicine, Suita, 565-0871, Japan.

Pathology, Research and Practice
|May 31, 2017
PubMed
Summary

Nonequilibrium atmospheric pressure plasma (NEAPP) offers a novel therapeutic avenue. Plasma-activated medium (PAM) derived from NEAPP effectively induces plasma cell differentiation in lymphoplasmacytic lymphoma (LPL) cells, reducing their tumor-forming potential.

Keywords:
CD138DifferentiationLymphoplasmacytic lymphomaPlasma-activated medium

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K

Related Experiment Videos

Last Updated: Mar 1, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K

Area of Science:

  • Biomedical Engineering
  • Plasma Physics
  • Oncology

Background:

  • Nonequilibrium atmospheric pressure plasma (NEAPP) is a promising technology with applications in medicine.
  • Plasma-activated medium (PAM) is a conserved, portable medium derived from NEAPP, offering an alternative to direct plasma application.
  • Lymphoplasmacytic lymphoma (LPL) is a hematological malignancy with a tumorigenic cell population.

Purpose of the Study:

  • To investigate the effects of PAM on lymphoplasmacytic lymphoma (LPL) cell lines.
  • To determine if PAM can induce differentiation and reduce the tumorigenic potential of LPL cells.
  • To explore the underlying molecular mechanisms of PAM's action on LPL cells.

Main Methods:

  • Treatment of LPL cell lines with PAM.
  • Analysis of cell differentiation markers.
  • Quantification of tumorigenic cell populations.
  • Assessment of PRDM1α gene expression.

Main Results:

  • PAM treatment induced significant plasma cell differentiation in LPL cell lines.
  • PAM significantly reduced the tumorigenic population of LPL cells.
  • PAM increased the expression of PRDM1α, a key transcription factor for plasma cell differentiation.

Conclusions:

  • PAM treatment promotes plasma cell differentiation in LPL, potentially mediated by PRDM1α.
  • PAM may represent a novel therapeutic strategy for LPL by converting tumorigenic cells to a less malignant phenotype.
  • The findings suggest a potential transition from tumorigenic to non-tumorigenic cell populations following PAM treatment.